Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM83SEB)

Drug Name
Faricimab Drug Info
Synonyms RO6867461; RG7716
Indication
Disease Entry ICD 11 Status REF
Diabetic macular edema 9B71.02 Approved [1]
Neovascular age-related macular degeneration 9B78.3Z Approved [1]
Cross-matching ID
TTD Drug ID
DM83SEB

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin-2 (ANGPT2) TTKLQTJ ANGP2_HUMAN Not Available [2]
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 8.544 6.927 7.253 7.839
Angiopoietin-2 (ANGPT2) DTT ANGPT2 2.036 2.472 1.722 3.433
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diabetic macular edema
ICD Disease Classification 9B71.02
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 3.61E-01 0.15 0.47
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761235.
2 Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.